3 completed, 3 unknown, 1 withdrawn. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Unknown 3, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow SARS Pneumonia: new trials by email Literature Review of SARS Pneumonia trials Research Report on SARS Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand Normal Saline, NDV-HXP-S vaccine - Covid-19, SARS Pneumonia | Phase 1 / Phase 2 | Completed | Mahidol University | 455 | 2021-03-20 | 2022-11-15 |
| Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management Niclosamide Oral Tablet - Covid-19, SARS Pneumonia | Phase 2 | Unknown | University of Baghdad | 150 | 2021-01-03 | 2021-06-22 |
| A Study of Combination Therapies to Treat COVID-19 Infection hydroxychloroquine, Azithromycin, Ritonavir - COVID, COVID-19 | Phase 2 | Withdrawn | ProgenaBiome | 2020-07-01 | 2021-04-08 | |
| Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial Convalescent Plasma of patients with COVID-19, placebo (hartmann plus albumine) - SARS Pneumonia | Phase 2 | Completed | Grupo Mexicano para el Estudio de la Medicina Intensiva | 42 | 2020-05-20 | 2020-12-21 |
| Baricitinib Compared to Standard Therapy in Patients With COVID-19 Baricitinib Oral Tablet - Covid-19, SARS-CoV 2 | Phase 2 | Unknown | Azienda Ospedaliero, Universitaria Pisana | 126 | 2020-05-20 | 2020-05-20 |
| Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma - Corona Virus Infection, SARS-CoV 2 | Phase 2 | Completed | University of Virginia | 29 | 2020-05-05 | 2022-04-01 |
| Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis Tocilizumab - SARS Pneumonia | Phase 2 | Unknown | Università Politecnica delle Marche | 38 | 2020-03-12 | 2020-04-13 |
COVID-19 (4) · Coronavirus Infections (2) · Pneumonia (2) · Pneumonia, Viral (1)
Coronaviridae Infections (5) · Infections (5) · Lung Diseases (5) · Nidovirales Infections (5) · RNA Virus Infections (5) · Respiratory Tract Diseases (5) · Respiratory Tract Infections (5) · Virus Diseases (5) · Coronavirus Infections (3) · Pneumonia (3) · Pneumonia, Viral (3)
Azithromycin (1) · Hydroxychloroquine (1) · Lopinavir (1) · NDV-HXP-S COVID-19 vaccine (1) · Niclosamide (1) · Ritonavir (1) · Saline Solution (1) · baricitinib (1) · tocilizumab (1)
Azienda Ospedaliero, Universitaria Pisana (1) · Grupo Mexicano para el Estudio de la Medicina Intensiva (1) · Mahidol University (1) · ProgenaBiome (1) · University of Baghdad (1) · University of Virginia (1) · Università Politecnica delle Marche (1)
Italy (2) · United States (2) · Iraq (1) · Mexico (1) · Thailand (1)
Ahmed S Abdulamir, Professor (1) · Faiq I. Gorial, Prof (1) · Francesco Menichetti, MD (1) · Punnee Pitisutthithum (1) · Sabine Hazan, MD (1) · Thomas Borody, MD, PhD, (1)
PMID 32032529, PMID 32251638, PMID 33307107, PMID 34580673, PMID 35284808